HC Wainwright Trims KalVista Pharmaceuticals (NASDAQ:KALV) Target Price to $20.00

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective reduced by HC Wainwright from $24.00 to $20.00 in a research report report published on Friday morning, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Separately, Needham & Company LLC reiterated a buy rating and set a $35.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, May 1st.

KalVista Pharmaceuticals Price Performance

KALV stock traded up $0.01 during mid-day trading on Friday, reaching $12.14. 193,069 shares of the company traded hands, compared to its average volume of 692,090. The company has a market capitalization of $512.19 million, a P/E ratio of -3.83 and a beta of 0.92. KalVista Pharmaceuticals has a 52-week low of $7.21 and a 52-week high of $16.88. The company has a fifty day moving average price of $12.12 and a 200-day moving average price of $11.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). As a group, analysts forecast that KalVista Pharmaceuticals will post -3.05 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par purchased 4,474 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were acquired at an average cost of $14.74 per share, with a total value of $65,946.76. Following the purchase, the insider now directly owns 4,743,157 shares of the company’s stock, valued at $69,914,134.18. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CFO Benjamin L. Palleiko sold 22,802 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total transaction of $321,736.22. Following the transaction, the chief financial officer now directly owns 187,315 shares of the company’s stock, valued at $2,643,014.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Venrock Healthcare Capital Par bought 4,474 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 6th. The shares were acquired at an average cost of $14.74 per share, for a total transaction of $65,946.76. Following the completion of the purchase, the insider now directly owns 4,743,157 shares of the company’s stock, valued at approximately $69,914,134.18. The disclosure for this purchase can be found here. Insiders have sold 75,978 shares of company stock valued at $1,070,918 in the last ninety days. Company insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently made changes to their positions in KALV. Quantbot Technologies LP purchased a new stake in KalVista Pharmaceuticals in the third quarter worth $31,000. Tower Research Capital LLC TRC grew its stake in KalVista Pharmaceuticals by 28.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock worth $43,000 after purchasing an additional 768 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in KalVista Pharmaceuticals in the fourth quarter worth $49,000. AJOVista LLC purchased a new stake in KalVista Pharmaceuticals in the fourth quarter worth $60,000. Finally, New York State Common Retirement Fund grew its stake in KalVista Pharmaceuticals by 1,860.4% in the third quarter. New York State Common Retirement Fund now owns 9,959 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 9,451 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.